Sign in to continue:

Saturday, July 25th, 2026

Expensify, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ

Expensify, Inc. Regains Nasdaq Compliance: Key Developments for Investors

Summary: Expensify, Inc. (NASDAQ: EXFY) has announced a significant regulatory update that is highly relevant for shareholders and may impact the company’s share price. Below are the key points and detailed analysis of the recent SEC filing.


Key Points from the SEC Report

  • Nasdaq Compliance Issue: Expensify, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department on April 17, 2026. The letter indicated that for 30 consecutive business days, the closing bid price for Expensify’s Class A common stock was below the minimum \$1.00 required for continued listing on the Nasdaq Global Select Market, pursuant to Nasdaq Listing Rule 5450(a)(1).
  • Regained Compliance: On May 28, 2026, Expensify was notified by Nasdaq that for the last 10 consecutive business days (from May 13, 2026 to May 27, 2026), the closing bid price of its Class A common stock had been at \$1.00 per share or greater. As a result, the company has regained compliance with the minimum bid price requirement, and Nasdaq considers this matter closed.
  • Stock Information: The company’s Class A common stock, par value \$0.0001 per share, trades under the symbol EXFY on the Nasdaq Stock Market LLC.
  • Corporate Details: Expensify, Inc. is incorporated in Delaware and its main address is 88 Kearny St, Ste 1600, San Francisco, CA 94108.
  • Officer Signature: The filing was signed by Chief Financial Officer Ryan Schaffer on May 29, 2026.

Shareholder Impact and Price Sensitivity

  • Potential Share Price Movement: The restoration of compliance with Nasdaq’s minimum bid price requirement removes the immediate risk of delisting, which could have had a severe negative impact on share value and investor sentiment. This positive regulatory outcome may support share price stability or potentially drive upward movement as market fears are alleviated.
  • Regulatory and Listing Status: Maintaining Nasdaq listing is critical for liquidity, visibility, and investor confidence. Any threat of delisting typically exerts downward pressure on the stock; conversely, resolution of such threats is often seen as a positive catalyst.
  • No Other Material Events: The filing confirms there are no written communications, soliciting materials, or tender offers related to mergers or acquisitions at this time, reducing the likelihood of other unexpected price-sensitive corporate actions.

Details for Investors

  • Trading Symbol: EXFY
  • Exchange: Nasdaq Stock Market LLC
  • Class of Security: Class A Common Stock, par value \$0.0001 per share
  • SEC File Number: 001-41043
  • EIN: 27-0239450
  • Business Address: 88 Kearny St, Ste 1600, San Francisco, CA 94108
  • Chief Financial Officer: Ryan Schaffer

Conclusion

This regulatory update is highly significant for Expensify shareholders. The resolution of the Nasdaq compliance issue removes a major risk factor and may positively influence the company’s share price. Investors should monitor trading activity and news for further developments, especially regarding operational performance and any future regulatory communications.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making any investment decisions. The information herein is based on publicly available SEC filings and may be subject to change.

View Expensify, Inc. Historical chart here



Hut 8 Corp. Form 8-K Filing Details: Address, Nasdaq Listing, and Executive Disclosure June 2026

Hut 8 Corp. Announces Results of 2026 Annual Meeting of Stoc...

MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment

MAIA Biotechnology Secures \$33 Million Capital Raise to Ful...

2024 Annual Report: Biotechnology Oncology Company – Targeted Therapies, ADC Strategy, Risk Factors & Financials

Immunome, Inc. 2025 Annual Report - Comprehensive Investor A...